Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model

By sjmartinez • May 24, 2023

Kabir M, Bergman RN, Porter J, Stefanovski D, Paszkiewicz RL, Piccinini F, Woolcott OO, Yang H, Gopaul VS, Stiles L, Kolka CM. Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model. Obesity (Silver Spring). 2023 May 23. doi: 10.1002/oby.23771. Epub ahead of print. PMID: 37221655.

Tags: Endocrinology, Publications

Pro-inflammatory macrophage activation does not require inhibition of oxidative phosphorylation

Ball AB, Jones AE, Nguyễn KB, Rios A, Marx N, Hsieh WY, Yang K, Desousa BR, Kim KKO, Veliova M, Del Mundo ZM, Shirihai OS,[...]

Cushing’s Disease Clinical Phenotype and Tumor Behavior Vary with Age: Diagnostic and Perioperative Implications

Salcedo-Sifuentes JE, Shih R, Heaney AP, Bergsneider M, Wang MB, Donangelo I, Lee J, Delery W, Karsy M, Kshettry VR, Yuen KCJ, Evans JJ, Barkhoudarian[...]

Recent developments in translational imaging of in vivo gene therapy outcomes

Day IL, Tamboline M, Lipshutz GS, Xu S. Recent developments in translational imaging of in vivo gene therapy outcomes. Mol Ther. 2024 Dec 30:S1525-0016(24)00849-9. doi:[...]